8-K current report · filed Oct 26, 2026

Xencor Inc (XNCR) 8-K Current Report: October 26, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 2.02Item 7.01XNCR overview

Short answer

Xencor Inc (XNCR) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Cash runway extended into 2029 under current operating plans, supporting continued research and development funding.

Xencor Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Cash runway extended into 2029 under current operating plans, supporting continued research and development funding
  • Runway depends on clinical-trial costs, timing and outcomes, operating changes, and collaboration or licensing revenue
  • Earlier capital depletion remains possible, preserving potential financing or partnering risk for shareholders

Item 7.01 · Regulation FD Disclosure

  • Xencor disclosed updated Phase 1 XmAb819 results in advanced clear cell renal cell carcinoma
  • XmAb819 is an ENPP3 x CD3 T-cell engaging bispecific antibody
  • Investor presentation furnished as Exhibit 99.1, providing the detailed clinical data
  • Results update may influence expectations for XmAb819’s development and oncology pipeline value

Item 8.01 · Other Events

  • Updated Phase 1 XmAb819 results in advanced clear cell renal cell carcinoma
  • XmAb819: ENPP3 x CD3 T-cell engaging bispecific antibody
  • Detailed efficacy and safety data available in Exhibit 99.2
  • Clinical update may influence XmAb819’s development path and Xencor’s oncology pipeline valuation

Item EX-99.1 · Exhibit EX-99.1

  • XmAb819 showed dose-dependent activity in heavily pretreated ccRCC: confirmed ORR 30% at 100 μg/kg, 44% at 200 μg/kg, and 45.5% at 400 μg/kg
  • Activity extended to resistant populations, with ORR 34.8% after prior HIF2α inhibitors and 45.2% after ≥2 VEGFR-TKIs
  • Safety remains the key development risk: Grade ≥3 events affected 82.4% of expansion-dose patients, including transaminase elevations and CRS
  • Commercial path advanced: potential registration-enabling study planned for 2027, with late-phase manufacturing activities already initiated
  • Xencor reported cash runway into 2029, supporting continued XmAb819 development without an immediate funding signal

Item EX-99.2 · Exhibit EX-99.2

  • XmAb819 selected at 400 mcg/kg IV, with 45.5% cORR, 55% uORR and 82% six-month PFS in 11 evaluable patients
  • Activity observed in heavily pretreated ccRCC, including 45% cORR after PD-(L)1 plus at least two VEGFR TKIs
  • Safety remains a key risk: 72.1% experienced grade 3 or higher related adverse events, though treatment discontinuation was 5.9%
  • Potential accelerated approval discussions with FDA planned for 1H2027 in exhausted-standard-of-care subgroups
  • Global randomized trial versus tivozanib planned, supporting potential full approval if successful beyond Phase 1 evidence

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Xencor Inc 8-K filings

Get the next XNCR 8-K as it lands

Follow XNCR for push alerts, or ask the research agent what this filing means.